down arrow

Ryvu Therapeutics SA

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLSELVT00013
PLN
26.30
0.3 (1.15%)

Dec 12

WAR

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
BIOTON SA
Biogened SA
Celon Pharma SA
Ryvu Therapeutics SA
Captor Therapeutics SA
Synthaverse SA
Bioceltix SA
Molecure SA
NanoGroup SA
Airway Medix SA
E-shopping Group SA
Why is Ryvu Therapeutics SA ?
1
Poor Management Efficiency with a low ROE of 0%
  • The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of 34.58% and Operating profit at -185.63% over the last 5 years
3
Flat results in Mar 25
  • INTEREST(HY) At PLN 3.34 MM has Grown at 986.97%
  • OPERATING CASH FLOW(Y) Lowest at PLN -117.89 MM
  • NET PROFIT(HY) At PLN -70.33 MM has Grown at -57.91%
4
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -46.16%, its profits have fallen by -30.8%
5
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -46.16% returns in the last 1 year, the stock has also underperformed Poland WIG in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Ryvu Therapeutics SA for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Ryvu Therapeutics SA
-36.63%
-0.92
55.56%
Poland WIG
39.24%
1.84
20.48%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
34.58%
EBIT Growth (5y)
-185.63%
EBIT to Interest (avg)
-75.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
0.29
Tax Ratio
0.25%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.31
EV to EBIT
-3.48
EV to EBITDA
-3.73
EV to Capital Employed
75.89
EV to Sales
7.33
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2178.87%
ROE (Latest)
-129.70%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET PROFIT(HY)

Higher at PLN -70.33 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 131.32%

-19What is not working for the Company
INTEREST(HY)

At PLN 3.34 MM has Grown at 986.97%

OPERATING CASH FLOW(Y)

Lowest at PLN -117.89 MM

NET PROFIT(HY)

At PLN -70.33 MM has Grown at -57.91%

ROCE(HY)

Lowest at -74.5%

RAW MATERIAL COST(Y)

Grown by 54.41% (YoY

NET SALES(Q)

At PLN 16.93 MM has Fallen at -13.13%

Here's what is working for Ryvu Therapeutics SA
Net Profit
Higher at PLN -70.33 MM
than preceding 12 month period ended Mar 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (PLN MM)

Inventory Turnover Ratio
Highest at 131.32%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for Ryvu Therapeutics SA
Interest
At PLN 3.34 MM has Grown at 986.97%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (PLN MM)

Operating Cash Flow
Lowest at PLN -117.89 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (PLN MM)

Net Profit
At PLN -70.33 MM has Grown at -57.91%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is negative

Net Profit (PLN MM)

Net Sales
At PLN 16.93 MM has Fallen at -13.13%
over average net sales of the previous four periods of PLN 19.49 MM
MOJO Watch
Near term sales trend is negative

Net Sales (PLN MM)

Raw Material Cost
Grown by 54.41% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."